StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3075% below fair value
$4.61−0.40 (-7.98%)

Close on Nov 19, 2026Market cap $191.75MP/E –Yield –

RxSight gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

RxSight's gross profit for the twelve months ending Jun 30, 2026 was $98.87M, down 8.0% year over year. For fiscal 2025 it was $103.01M, up 4.1% from the year before. The highest annual figure on record is $103.01M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$103.01M+4.1%
FY2024Dec 31, 2024$98.94M+84.0%
FY2023Dec 31, 2023$53.77M+152.1%
FY2022Dec 31, 2022$21.33M+372.2%
FY2021Dec 31, 2021$4.52M+164.9%
FY2020Dec 31, 2020$1.71M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$25.89M+2.8%
Q1 FY2026Mar 31, 2026$23.50M-17.1%
Q4 FY2025Dec 31, 2025$25.26M-12.2%
Q3 FY2025Sep 30, 2025$24.23M-3.9%
Q2 FY2025Jun 30, 2025$25.19M+3.9%
Q1 FY2025Mar 31, 2025$28.33M+37.0%
Q4 FY2024Dec 31, 2024$28.79M+63.1%
Q3 FY2024Sep 30, 2024$25.22M+83.7%
Q2 FY2024Jun 30, 2024$24.25M+101.8%
Q1 FY2024Mar 31, 2024$20.69M+99.5%
Q4 FY2023Dec 31, 2023$17.65M+137.9%
Q3 FY2023Sep 30, 2023$13.73M+156.4%
Q2 FY2023Jun 30, 2023$12.02M+150.9%
Q1 FY2023Mar 31, 2023$10.37M+175.6%
Q4 FY2022Dec 31, 2022$7.42M+158.7%
Q3 FY2022Sep 30, 2022$5.36M+299.4%
Q2 FY2022Jun 30, 2022$4.79M–
Q1 FY2022Mar 31, 2022$3.76M+236.1%
Q4 FY2021Dec 31, 2021$2.87M+107.9%
Q3 FY2021Sep 30, 2021$1.34M+86.3%
Q2 FY2021Jun 30, 2021-$812.00K–
Q1 FY2021Mar 31, 2021$1.12M–
Q4 FY2020Dec 31, 2020$1.38M–
Q3 FY2020Sep 30, 2020$720.00K–
Q2 FY2020Jun 30, 2020-$474.00K–

More RxSight figures

See a number that looks wrong?